VERTEX PHARMACEUTICALS INC / MA (VRTX) stock intrinsic value fair value estimate & owner earnings analysis

Vertex is the dominant maker of medicines that treat the underlying cause of cystic fibrosis. Trikafta (Kaftrio in Europe) produced $10.3 billion of 2025 revenue and the newer once-daily Alyftrek another $0.8 billion, so cystic fibrosis is roughly 95% of a $12.0 billion business. Newer products - Casgevy, a one-time gene-edited therapy for sickle cell disease and beta thalassemia shared with CRISPR Therapeutics, and Journavx, a non-opioid acute pain pill launched in 2025 - are still small. Revenue came 63% from the United States, 29% from Europe and 8% elsewhere. Earnings power. We measure owner earnings as operating cash flow with working-capital swings removed, less the real cost of stock compensation and the capital spending needed to maintain the business. On that basis Vertex earned $12.10 per share in 2022, $11.71 in 2023, $13.42 in 2024 and $14.48 in 2025. Two accounting judgements matter. First, the 2024 figure adds back the $4.4 billion Alpine Immune Sciences purchase, which accounting rules forced through operating expenses because it was an asset purchase; it is an acquisition cost, not a cost of running the business. Smaller licensing and milestone payments (for example $900 million to CRISPR in 2021, $527 million in 2023) recur every year and are left in as an ordinary cost. Second, 2025 operating cash flow looked weak only because Vertex built about $1.2 billion of receivables, inventory and prepaid items for its launches; stripping out that build shows the underlying earnings kept rising. We use 2022-2025 as the representative window (the business before 2020 was a much smaller, pre-Trikafta company) and take a level of about $13.10 per share after removing roughly $1.45 per share of interest earned on the company's cash, since that cash is counted separately. Owner earnings grew 7.9% in 2025; the base case assumes 5% in year one, below that rate. Balance sheet. Vertex holds about $13.6 billion of cash and marketable securities at June 2026 against only $112 million of finance leases and no bonds. We treat about $1.5 billion as needed to run the business, leaving roughly $47 per share of surplus cash, which is added to every case except the bear case, where we count only half because the company has a long record of spending cash on acquisitions whose payoff is uncertain. The central fact is patent life. The 10-K dates the U.S. basic patent on Trikafta to 2037 and Alyftrek to 2039; Kalydeco (2028), Symdeko (2027) and Orkambi (2031) expire sooner but are already small. Small-molecule drugs typically lose most of their sales within two to three years of generic entry, and nothing in today's portfolio replaces $11 billion of cystic fibrosis revenue. So every case is a story with an end: years of strong cash, then a steep fade. Base case ($230 per share). Earnings of $13.10 grow about 5% a year through 2030 as patients switch to Alyftrek, younger children become eligible, and Casgevy and Journavx contribute - all already-approved products. Growth slows to 3% through 2036, then declines as Trikafta generics arrive in 2037 and Alyftrek generics in 2039, falling to about a quarter of peak by 2041; after that we credit only what the research engine has demonstrably sustained - a continuing stream at roughly 25% of peak - reflecting Vertex's record of producing a new major cystic fibrosis medicine every few years for two decades. The business is worth about $183 per share, owes essentially nothing, and adds $47 of surplus cash. Bear case ($119 per share). Earnings start at $11.50 and do not grow. Two named pressures already disclosed in the 10-K bite: U.S. government drug-pricing measures (Medicare Part D redesign, the most-favored-nation pricing push, state drug-affordability boards) cut net prices about 10% from 2030, and Royalty Pharma's October 2025 arbitration claim, which argues Alyftrek owes about an 8% royalty rather than the 4% Vertex pays, goes against the company. Trikafta generics arrive on schedule in 2037 and earnings collapse to about a quarter of today's within three years, leaving a small residual stream for 15 years and nothing after. No pipeline success is credited. The business is worth about $96 per share; with only half the surplus cash credited, the shares are worth about $119. There is no debt, so even this case carries no refinancing risk. Bull case ($303 per share). Earnings start at $14.50 (close to 2025's actual level) and grow 7% a year to 2031 - in line with recent actual owner-earnings growth - and 4% to 2037 as Alyftrek's later patent shifts most patients onto 2039 protection. The decline is delayed and a larger residual (about 40% of peak) persists from the next generation of approved products. Approval of povetacicept for IgA nephropathy or the type 1 diabetes cell therapy zimislecel is not credited in any case, because neither is yet approved. What would make this wrong: an earlier generic entry through a successful patent challenge (none is disclosed today); a U.S. pricing law that reaches cystic fibrosis drugs, which are currently excluded from Medicare negotiation; or management spending the cash pile on another multi-billion-dollar acquisition that fails. Margin-of-safety price. We are fairly sure of the earnings level: four straight years between $11.70 and $14.50 per share, from a disease where patients take the drug for life and switching is rare. The worst plausible outcome is a pricing shock in the United States combined with the loss of the royalty arbitration, followed by the patent cliff - roughly the bear case - and the structure survives it easily because there is no debt and $13.6 billion of cash. The biggest risk is not survival but concentration: one disease and, after 2037, one cliff. If we are wrong about growth and the residual after 2040, the shares are still worth around $120-$140 on the cash already being generated plus the cash on hand. The company pays no dividend; it returns cash through buybacks ($2.0 billion in 2025), which lift per-share value while waiting. Owner earnings of about $13 per share are a 13-14% cash yield at $95, and about half of that price is covered by surplus cash plus two years of earnings. Assuming a five-year holding period from $95, the business would generate roughly $70 per share of owner earnings plus the cash on hand, while the patent runway past 2037 would still be intact, which is what is needed for the shares to compound near 20% a year. Above about $100, the return depends on the market recognising value we cannot count on, so the margin-of-safety price is $95. Our previous estimate overstated the bull case by assuming growth continuing well beyond the patent dates now disclosed in the filings; the patent schedule lowers the bull value, while the much stronger 2025 cash earnings once launch inventory builds are stripped out raise the bear value.